Elizabeth H. Cull
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Elizabeth H. Cull

Oncology | Hematology Oncology
Prisma Health
Prisma Health Cancer Institute – Eastside
65 International Drive, 
Greenville, SC 
On Staff At
Accepting New Patients
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Prisma Health
Prisma Health Cancer Institute – Eastside
65 International Drive, 
Greenville, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Cull is a Hematologist Oncology specialist and an Oncologist in Greenville, South Carolina. Dr. Cull is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Cull is currently accepting new patients.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Graduate Institution
Bowman Gray School Of Medicine Of Wake Forest University
Residency
Northwestern University Medical School
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine
Fellowships
Northwestern University Medical School
Hospital Affiliations
Prisma Health Greer Memorial Hospital
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Prisma Health Baptist Easley Hospital
Prisma Health Hillcrest Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Prisma Health Cancer Institute – Eastside
65 International Drive, Greenville, SC 29615
Call: 864-987-7000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Withdrawn
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: May 20, 2021
Intervention Type: Biological
Study Drugs: Rituximab, Obinutuzumab, Idelalisib, Ibrutinib, Bendamustine, TRU-016
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 9 Less Clinical Trials

16 Total Publications

Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Journal: Journal of adolescent and young adult oncology
Published: July 03, 2024
View All 16 Publications
Similar Doctors
Suzanne R. Fanning
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Suzanne R. Fanning
Oncology | Hematology Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Suzanne R. Fanning
Oncology | Hematology Oncology

Prisma Health Cancer Institute – Eastside

65 International Drive, 
Greenville, SC 
 (0.2 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzanne Fanning is a Hematologist Oncology specialist and an Oncologist in Greenville, South Carolina. Dr. Fanning is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Fanning is currently accepting new patients.

Saeeda Z. Chowdhury
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Saeeda Z. Chowdhury
Oncology | Hematology Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Saeeda Z. Chowdhury
Oncology | Hematology Oncology

Prisma Health Cancer Institute – Eastside

65 International Drive, 
Greenville, SC 
 (0.2 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saeeda Chowdhury is a Hematologist Oncology specialist and an Oncologist in Greenville, South Carolina. Dr. Chowdhury is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Large-Cell Immunoblastic Lymphoma, Multiple Myeloma, Paget Disease of the Breast, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Chowdhury is currently accepting new patients.

Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Tondre T. Buck
Hematology Oncology | Oncology | Hematology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Tondre T. Buck
Hematology Oncology | Oncology | Hematology

Spartanburg Medical Center

101 E Wood St, 
Spartanburg, SC 
 (23.0 miles away)
864-560-6193
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tondre Buck is a Hematologist Oncology specialist and an Oncologist in Spartanburg, South Carolina. Dr. Buck is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, Thrombocytopenia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Buck is currently accepting new patients.

VIEW MORE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cull's expertise for a condition
ConditionClose
    • Distinguished
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Cull is
      Distinguished
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Cull is
      Distinguished
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Chronic Lymphocytic Leukemia (CLL)
      Dr. Cull is
      Distinguished
      . Learn about Chronic Lymphocytic Leukemia (CLL).
      See more Chronic Lymphocytic Leukemia (CLL) experts
    • Diffuse Large B-Cell Lymphoma (DLBCL)
      Dr. Cull is
      Distinguished
      . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
      See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
    • Familial Pancreatic Cancer
      Dr. Cull is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Large-Cell Immunoblastic Lymphoma
      Dr. Cull is
      Distinguished
      . Learn about Large-Cell Immunoblastic Lymphoma.
      See more Large-Cell Immunoblastic Lymphoma experts
    View All 9 Distinguished Conditions
    • Advanced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Cull is
      Advanced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Ataxia-Pancytopenia Syndrome
      Dr. Cull is
      Advanced
      . Learn about Ataxia-Pancytopenia Syndrome.
      See more Ataxia-Pancytopenia Syndrome experts
    • B-Cell Lymphoma
      Dr. Cull is
      Advanced
      . Learn about B-Cell Lymphoma.
      See more B-Cell Lymphoma experts
    • Bone Marrow Aspiration
      Dr. Cull is
      Advanced
      . Learn about Bone Marrow Aspiration.
      See more Bone Marrow Aspiration experts
    • Burkitt Lymphoma
      Dr. Cull is
      Advanced
      . Learn about Burkitt Lymphoma.
      See more Burkitt Lymphoma experts
    • Childhood Acute Myeloid Leukemia
      Dr. Cull is
      Advanced
      . Learn about Childhood Acute Myeloid Leukemia.
      See more Childhood Acute Myeloid Leukemia experts
    View All 26 Advanced Conditions
    • Experienced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Cull is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Cull is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Acute Mountain Sickness
      Dr. Cull is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myelomonocytic Leukemia
      Dr. Cull is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Acute Promyelocytic Leukemia
      Dr. Cull is
      Experienced
      . Learn about Acute Promyelocytic Leukemia.
      See more Acute Promyelocytic Leukemia experts
    • Adult Immune Thrombocytopenia
      Dr. Cull is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    View All 73 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.